Switch theme
Sign up to access all valuation multiples
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
2008
837
LTM Revenue $360M
LTM EBITDA $77.6M
$863M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MiMedx Group has a last 12-month revenue (LTM) of $360M and a last 12-month EBITDA of $77.6M.
In the most recent fiscal year, MiMedx Group achieved revenue of $349M and an EBITDA of $64.3M.
MiMedx Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MiMedx Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $360M | XXX | $349M | XXX | XXX | XXX |
| Gross Profit | $297M | XXX | $289M | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | $77.6M | XXX | $64.3M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $54.6M | XXX | $59.3M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $40.1M | XXX | $42.4M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MiMedx Group's stock price is $6.
MiMedx Group has current market cap of $950M, and EV of $863M.
See MiMedx Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $863M | $950M | XXX | XXX | XXX | XXX | $0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MiMedx Group has market cap of $950M and EV of $863M.
MiMedx Group's trades at 2.5x EV/Revenue multiple, and 13.4x EV/EBITDA.
Equity research analysts estimate MiMedx Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MiMedx Group has a P/E ratio of 23.7x.
See valuation multiples for MiMedx Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $950M | XXX | $950M | XXX | XXX | XXX |
| EV (current) | $863M | XXX | $863M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | 13.4x | XXX | XXX | XXX |
| EV/EBIT | 15.8x | XXX | 14.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.7x | XXX | 22.4x | XXX | XXX | XXX |
| EV/FCF | 14.1x | XXX | 13.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMiMedx Group's last 12 month revenue growth is 9%
MiMedx Group's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
MiMedx Group's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MiMedx Group's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MiMedx Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 38% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MiMedx Group acquired XXX companies to date.
Last acquisition by MiMedx Group was XXXXXXXX, XXXXX XXXXX XXXXXX . MiMedx Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MiMedx Group founded? | MiMedx Group was founded in 2008. |
| Where is MiMedx Group headquartered? | MiMedx Group is headquartered in United States of America. |
| How many employees does MiMedx Group have? | As of today, MiMedx Group has 837 employees. |
| Who is the CEO of MiMedx Group? | MiMedx Group's CEO is Mr. Joseph H. Capper. |
| Is MiMedx Group publicy listed? | Yes, MiMedx Group is a public company listed on NAS. |
| What is the stock symbol of MiMedx Group? | MiMedx Group trades under MDXG ticker. |
| When did MiMedx Group go public? | MiMedx Group went public in 2008. |
| Who are competitors of MiMedx Group? | Similar companies to MiMedx Group include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of MiMedx Group? | MiMedx Group's current market cap is $950M |
| What is the current revenue of MiMedx Group? | MiMedx Group's last 12 months revenue is $360M. |
| What is the current revenue growth of MiMedx Group? | MiMedx Group revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of MiMedx Group? | Current revenue multiple of MiMedx Group is 2.4x. |
| Is MiMedx Group profitable? | Yes, MiMedx Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MiMedx Group? | MiMedx Group's last 12 months EBITDA is $77.6M. |
| What is MiMedx Group's EBITDA margin? | MiMedx Group's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of MiMedx Group? | Current EBITDA multiple of MiMedx Group is 11.1x. |
| What is the current FCF of MiMedx Group? | MiMedx Group's last 12 months FCF is $61.2M. |
| What is MiMedx Group's FCF margin? | MiMedx Group's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of MiMedx Group? | Current FCF multiple of MiMedx Group is 14.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
